Research Article

After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia

Figure 3

Bone marrow aspirate- (BMA-) CD3, -CD4, -CD8, -NK, and -B lymphocyte count reduction after antineoplastic treatment, data shown as . BMA-CD3, -CD4, -CD8, -NK, and -B count reduction from 1638/μL (diagnostic phase: black bar) to 1222/μL (after treatment phase: red bar) (), 909/μL to 672/μL (), 657/μL to 496/μL, (), 341/μL to 208/μL (), and 883/μL to 34/μL (, Wilcoxon signed rank test), respectively.